There is a lack of robust evidence to assess the strength of other treatment options
Objectives Sarcopenia , defined as an age-associated loss of skeletal muscle function and muscle mass , occurs in approximately 6 - 22 % of older adults .
This paper presents evidence -based clinical practice guidelines for screening , diagnosis and management of sarcopenia from the task force of the International Conference on Sarcopenia and Frailty Research ( ICSFR ) .
A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia
Background Sarcopenia , the age-related loss of muscle mass [ defined as appendicular LBM/Height2 ( aLBM/ht2 ) below peak value by>1SD ] , strength and function , is a major contributing factor to frailty in the elderly .  MK-0773 is a selective and rogen receptor modulator design ed to improve muscle function while minimizing effects on other tissues . Objectives The primary objective of this study was to demonstrate an improvement in muscle strength and lean body mass ( LBM ) in sarcopenic frail elderly women treated with MK-0773 relative to placebo . Design This was a r and omized , double-blind , parallel-arm , placebo-controlled , multicenter , 6-month study . Participants were r and omized in a 1:1 ratio to receive either MK-0773 50 mg b.i.d . or placebo ; all participants received Vitamin D and protein supplementation . Setting General community . Participants 170 Women aged ≥65 with sarcopenia and moderate physical dysfunction . Measurements Dual energy X-ray absorptiometry , muscle strength and power , physical performance measures . Results Participants receiving MK-0773 showed a statistically significant increase in LBM from baseline at Month 6 vs. placebo ( p<0.001 ) . Participants receiving both MK-0773 and placebo showed a statistically significant increase in strength from baseline to Month 6 , but the mean difference between the two groups was not significant ( p=0.269 ) . Both groups showed significant improvement from baseline at Month 6 in physical performance measures , but there were no statistically significant differences between participants receiving MK-0773 and placebo . A greater number of participants experienced elevated transaminases in the MK-0773 group vs. placebo , which resolved after discontinuation of study therapy . MK-0773 was generally well-tolerated with no evidence of and rogenization . Conclusions The MK-0773-induced  increase in LBM did not translate to improvement in strength or function vs. placebo . The improvement of strength and physical function in the placebo group could be at least partly attributed to protein and vitamin D supplementation
There is a lack of robust evidence to assess the strength of other treatment options
Objectives Sarcopenia , defined as an age-associated loss of skeletal muscle function and muscle mass , occurs in approximately 6 - 22 % of older adults .
This paper presents evidence -based clinical practice guidelines for screening , diagnosis and management of sarcopenia from the task force of the International Conference on Sarcopenia and Frailty Research ( ICSFR ) .